Joshua Patterson
Keine laufenden Positionen mehr
Vermögen: 10 155 $ am 31.03.2024
Karriereverlauf von Joshua Patterson
Ehemalige bekannte Positionen von Joshua Patterson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GAMIDA CELL LTD. | Compliance Officer | 01.08.2021 | 26.04.2024 |
| General Counsel | 01.08.2021 | 26.04.2024 | |
| IONIS PHARMACEUTICALS, INC. | Director/Board Member | 01.12.2006 | 01.03.2018 |
| Corporate Officer/Principal | 01.12.2006 | 01.03.2018 | |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.10.2000 | 01.09.2006 |
| AKCEA THERAPEUTICS, INC. | General Counsel | 01.03.2018 | - |
| Corporate Secretary | 01.03.2018 | 11.03.2020 |
Ausbildung von Joshua Patterson
| Carthage College | Undergraduate Degree |
| Syracuse University | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
| Israel | 2 |
Operativ
| General Counsel | 2 |
| Corporate Officer/Principal | 2 |
| Corporate Secretary | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Joshua Patterson
- Erfahrung
